RenovoRx, Inc.
RNXT- Exchange
- Nasdaq
- Industry
- Surgical & Medical Instruments & Apparatus
- SEC CIK
- 0001574094
No open-market purchases or sales by RenovoRx, Inc. insiders were filed in the last 90 days; 28 institutions reported holding it in 13F filings for Q2 2026, worth $9.00M in total; no superinvestor holds it.
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsOpen market, last 90 days
- 0
- 13F holdersQ2 2026, −3 vs. previous quarter
- 28
- 13F valueReported value at the end of Q2 2026
- $9.00M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RNXT, Q2 2026
No superinvestor reported holding RNXT at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by RenovoRx, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| May 21, 2026 (view filing) | May 19 | 2 days | Voll MarkChief Financial Officer | PPurchase | +25.0K | $0.79 | +$19.8K | +21.3%142.4K after | |
| Mar 24, 2026 (view filing) | Mar 20 | 4 days | Marton LaurenceDirector | PPurchase | +9.72K | – | – | New position9.72K after | |
| Mar 24, 2026 (view filing) | Mar 20 | 4 days | Marton LaurenceDirector | PPurchase | +4.86K | – | – | –4.86K after | Derivative |
| Mar 24, 2026 (view filing) | Mar 20 | 4 days | Bagai ShaunChief Executive Officer | PPurchase | +24.3K | – | – | +8.4%313.4K after | |
| Mar 24, 2026 (view filing) | Mar 20 | 4 days | Bagai ShaunChief Executive Officer | PPurchase | +12.2K | – | – | –12.2K after | Derivative |
| Mar 24, 2026 (view filing) | Mar 20 | 4 days | Voll MarkChief Financial Officer | PPurchase | +97.2K | – | – | New position97.2K after | |
| Mar 24, 2026 (view filing) | Mar 20 | 4 days | Voll MarkChief Financial Officer | PPurchase | +48.6K | – | – | –48.6K after | Derivative |
| Jan 22, 2026 (view filing) | Jan 21 | 1 day | Agah RamtinChief Medical Officer | PPurchase | +10.0K | $1.00 | +$10.0K | +1.3%798.5K after | |
| Jan 5, 2026 (view filing) | Dec 31, 2025 | 5 days | Agah RamtinChief Medical Officer | PPurchase | +9.79K | $0.86 | +$8.42K | +1.3%788.5K after | |
| Jan 2, 2026 (view filing) | Dec 30, 2025 | 3 days | Agah RamtinChief Medical Officer | PPurchase | +205 | $0.83 | +$170.15 | 0.0%778.7K after |
Top 10 13F holders, Q2 2026
The largest institutional positions in RenovoRx, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| AIGH Capital Management LLC | 4,405,439 | $4.32M | 0.39% | +699,242+18.9% | Added |
| Bleichroeder LP | 1,666,098 | $1.63M | 0.29% | 00.0% | Unchanged |
| Vanguard Capital Management LLC | 1,443,742 | $1.41M | 0.00% | −3,435−0.2% | Reduced |
| Geode Capital Management, LLC | 424,148 | $415.7K | 0.00% | +42,425+11.1% | Added |
| Wealthspire Advisors, LLC | 252,525 | $247.5K | 0.00% | 00.0% | Unchanged |
| Vanguard Fiduciary Trust Co | 240,330 | $235.5K | 0.00% | +82,428+52.2% | Added |
| Citadel Advisors LLC | 133,597 | $130.9K | 0.00% | −99,087−42.6% | Reduced |
| Northern Trust Corp | 85,207 | $83.5K | 0.00% | +43,046+102.1% | Added |
| Chicago Partners Investment Group LLC | 92,356 | $78.9K | 0.00% | 00.0% | Unchanged |
| Northwestern Mutual Wealth Management Co | 74,596 | $73.1K | 0.00% | −24,864−25.0% | Reduced |